Intuitive Surgical
ISRG
$0.00
-0.39%
Intuitive Surgical Inc. is a global leader in robotic-assisted minimally invasive surgery, primarily known for its da Vinci surgical systems. The company operates as a dominant platform provider in the medical instruments and supplies industry, with its business model encompassing the sale of high-margin robotic systems, instruments, accessories, and service contracts. The current investor narrative is dominated by the tension between strong underlying business performance, evidenced by recent earnings beats and raised long-term growth forecasts, and significant regulatory and product safety headwinds, such as an FDA flag on a surgical stapler, which have introduced volatility and debate about the stock's near-term risk profile.…
ISRG
Intuitive Surgical
$0.00
Related headlines
Investment Opinion: Should I buy ISRG Today?
Rating & Thesis: Hold. ISRG is a fundamentally superb company trapped in an overvalued stock, requiring patience for a better entry point or clear resolution of regulatory overhangs. The bullish analyst consensus and estimated EPS growth are compelling, but the current price does not offer an adequate margin of safety.
Supporting Evidence: The recommendation is grounded in four specific data points: 1) The forward P/E of 37.16x is a steep premium to most medical device peers, 2) Revenue growth, while strong at 18.8% YoY, must be sustained to justify this multiple, 3) The stock trades 27% below its 52-week high, indicating the market is already punishing the valuation, and 4) The implied earnings growth from a $2.24 quarterly EPS to a $17.08 forward annual estimate is extraordinarily ambitious. The fortress balance sheet (D/E 0.017) and high margins are supportive but already reflected in the price.
Risks & Conditions: The two biggest risks are multiple compression from sustained high interest rates and a worsening of the FDA regulatory situation. This Hold rating would upgrade to a Buy if the forward P/E compressed meaningfully below 30x (offering a better risk/reward) or if the company demonstrates several quarters of growth exceeding the high bar set by estimates. It would downgrade to a Sell if revenue growth decelerates below 15% or if the regulatory issue materially impacts financial guidance. Relative to its own history and growth profile, the stock is currently fairly valued to slightly overvalued, demanding perfection.
Sign up to view all
ISRG 12-Month Price Forecast
The AI assessment is neutral based on a clash between stellar fundamentals and prohibitive valuation. The company's 18.8% revenue growth, 66% gross margins, and zero debt are hallmarks of a quality compounder. However, the stock's 70x trailing P/E and 37x forward P/E leave no room for error, a concern amplified by recent regulatory noise and a 19% price decline. The stance would upgrade to bullish if the stock approaches its 52-week low (~$418), offering a compelling margin of safety, or if the FDA issue is resolved favorably alongside another strong earnings beat. It would turn bearish if revenue growth decelerates below 15% or if operating margins show unexpected contraction.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Intuitive Surgical's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
15 analysts
Implied Upside
—
vs. current price
Analyst Count
15
covering this stock
Price Range
$0 - $0
Analyst target range
The stock is covered by 15 analysts, and the consensus sentiment leans bullish, as evidenced by recent actions like Citigroup's upgrade to 'Buy' and multiple firms maintaining 'Overweight' or 'Outperform' ratings. The average target price is derived from estimated EPS of $17.08 and revenue of $18.74 billion, though a specific consensus price target is not provided in the data. The target range shows high conviction in the long-term story but also uncertainty, with a low EPS estimate of $16.40 and a high of $18.17. The high target likely assumes successful navigation of regulatory issues, continued market share gains, and multiple expansion, while the low target may factor in increased competition or margin pressures. A pattern of recent analyst actions shows a mix of reiterations and one notable upgrade, suggesting stability in the bullish thesis among institutional followers despite recent stock price weakness.
Bulls vs Bears: ISRG Investment Factors
The investment debate for ISRG centers on the tension between its impeccable fundamental execution and its extreme valuation amid growing external risks. The bull case, supported by 18.8% revenue growth, 66% gross margins, and a fortress balance sheet, is currently stronger on an operational basis. However, the bear case holds significant weight in the near term due to a 19% stock price decline, regulatory concerns, and a valuation that prices in perfection. The single most important tension is whether the company's robust growth and profitability can sustainably justify its premium valuation (70.78x trailing P/E) in the face of potential multiple compression for growth stocks and regulatory overhangs. The resolution of the FDA stapler issue and the next few quarters' earnings growth relative to the high bar set by the forward P/E will be decisive.
Bullish
- Robust Revenue Growth: Quarterly revenue grew 18.76% YoY to $2.87B, driven by strong system placements and procedure volume. This consistent double-digit growth reinforces the company's dominant market position and underlying demand.
- Exceptional Profitability & Margins: The company boasts a trailing net margin of 28.38% and a quarterly gross margin of 66.44%. This high profitability, coupled with an operating margin of 29.27%, demonstrates efficient scaling of its premium business model.
- Fortress Balance Sheet: ISRG has virtually no debt, with a debt-to-equity ratio of 0.017, and exceptional liquidity with a current ratio of 4.87. It generates substantial free cash flow ($2.49B TTM), providing a massive buffer for R&D and strategic moves.
- Strong Analyst Conviction: Coverage by 15 analysts shows a bullish consensus, including recent upgrades. The forward EPS estimate of $17.08 implies significant earnings growth from the current $2.24, signaling confidence in the long-term trajectory.
Bearish
- Extreme Valuation Premium: The stock trades at a trailing P/E of 70.78x and a forward P/E of 37.16x, a significant premium to medical device peers. This lofty valuation leaves no room for error and makes the stock vulnerable to multiple compression.
- Pronounced Technical Downtrend: The stock is down 19.27% over the past year and 13.08% over the past three months, trading 27% below its 52-week high. Persistent negative momentum and a beta of 1.509 amplify downside volatility and investor concern.
- Regulatory & Product Safety Headwinds: Recent FDA flags on a surgical stapler introduce significant near-term risk. Such regulatory scrutiny can impact reputation, trigger recalls, and slow adoption, creating volatility despite strong fundamentals.
- High Growth Expectations Priced In: The wide gap between trailing (70.78x) and forward (37.16x) P/E ratios implies the market expects EPS to nearly octuple. Any deceleration in growth or procedure volumes would severely disappoint these baked-in expectations.
ISRG Technical Analysis
The stock is in a pronounced downtrend, having declined 19.27% over the past year. With a current price of $438.10, it is trading near the lower end of its 52-week range, approximately 28% above its 52-week low of $417.74 but 27% below its 52-week high of $603.88. This positioning suggests the stock is in a deep correction phase, potentially offering a value entry point but also reflecting significant negative momentum and investor concern. Recent momentum remains decisively negative, with the stock down 9.41% over the past month and 13.08% over the past three months, indicating the selling pressure has accelerated relative to the longer-term trend. This persistent weakness is underscored by a relative strength reading of -14.25 against the S&P 500 over the past month, highlighting significant underperformance. Key technical support is clearly defined at the 52-week low of $417.74, while resistance sits at the recent highs near the 52-week high of $603.88. A breakdown below support could signal a new leg down, whereas a sustained move above resistance would be needed to invalidate the bearish trend. The stock's beta of 1.509 indicates it is approximately 50% more volatile than the broader market, which amplifies both downside risk and potential upside during a recovery.
Beta
1.51
1.51x market volatility
Max Drawdown
-29.1%
Largest decline past year
52-Week Range
$418-$604
Price range past year
Annual Return
-19.3%
Cumulative gain past year
| Period | ISRG Return | S&P 500 |
|---|---|---|
| 1m | -9.4% | +4.4% |
| 3m | -13.1% | +8.5% |
| 6m | -22.0% | +9.7% |
| 1y | -19.3% | +28.8% |
| ytd | -22.0% | +9.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ISRG Fundamental Analysis
Revenue growth remains robust, with the most recent quarterly revenue of $2.87 billion representing a year-over-year increase of 18.76%. This growth is being driven across business segments, with Instruments and Accessories ($1.66B) and Systems ($785.9M) leading the way, indicating strong procedure volume and system placements. The multi-quarter trend shows consistent double-digit growth, reinforcing the company's dominant market position and underlying demand for robotic surgery. The company is highly profitable, posting net income of $794.8 million for the quarter and a trailing net margin of 28.38%. Gross margins are exceptionally strong at 66.44% for the quarter, consistent with the company's premium pricing and razor-and-blades business model. Operating margins are also healthy at 29.27%, demonstrating efficient scaling of its high-growth business. The balance sheet is fortress-like, with a minimal debt-to-equity ratio of 0.017, indicating virtually no financial leverage risk. The company generates substantial cash, with trailing twelve-month free cash flow of $2.49 billion, providing ample internal funding for R&D, share buybacks, and strategic initiatives. Return on equity is a solid 16.02%, reflecting efficient use of shareholder capital, while a current ratio of 4.87 highlights exceptional short-term liquidity.
Quarterly Revenue
$2.9B
2025-12
Revenue YoY Growth
+0.18%
YoY Comparison
Gross Margin
+0.66%
Latest Quarter
Free Cash Flow
$2.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ISRG Overvalued?
Given the company's substantial net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E is elevated at 70.78x, while the forward P/E is significantly lower at 37.16x. This wide gap implies the market is pricing in a substantial acceleration in earnings growth, with analysts expecting EPS to rise from $2.24 to an estimated $17.08. Compared to industry averages, ISRG trades at a significant premium. Its forward P/E of 37.16x is well above typical medical device peers, and its Price-to-Sales ratio of 20.08x is also lofty. This premium is justified by the company's market-leading position, superior growth profile (18.8% YoY revenue growth), and exceptional profitability metrics, but it also leaves little room for execution error. Historically, the stock's current trailing P/E of 70.78x is near the upper end of its own historical range observed over recent years, which has typically fluctuated between the 50s and 70s. Trading near historical highs on a trailing basis suggests the market has already priced in optimistic expectations for future growth and margin expansion, making the stock vulnerable to multiple compression if growth decelerates.
PE
70.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 49x~84x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
55.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: While ISRG's financials are exceptionally strong, the primary risk is valuation dependence on flawless execution. The forward P/E of 37.16x demands that estimated EPS of $17.08 is achieved, implying earnings must grow nearly 8x from the recent quarterly EPS of $2.24. Any stumble in revenue growth, which has been a consistent 18-19% YoY, or margin pressure from competitive or pricing dynamics, could trigger a severe derating. Furthermore, despite minimal debt, the company's sky-high Price-to-Sales ratio of 20.08x indicates the market is pricing in decades of future growth, creating inherent vulnerability.
Market & Competitive Risks: The stock faces significant market risk due to its premium valuation and high beta of 1.509, making it 50% more volatile than the market. In a risk-off environment or one where interest rates remain elevated, growth stocks with high multiples are often sold first. The stock's 27% discount to its 52-week high and severe underperformance (-47% relative strength vs. S&P 500) evidence this compression is already underway. Competitively, while ISRG dominates now, the regulatory headwind highlighted by the FDA stapler flag provides an opening for rivals and could slow the adoption curve for new system placements.
Worst-Case Scenario: The worst-case scenario involves a combination of the FDA stapler issue escalating into a broader product safety review, concurrent with a macroeconomic slowdown that causes hospitals to delay capital expenditures on new da Vinci systems. This could lead to a material miss on both revenue growth and the high forward EPS estimates. In this adverse scenario, the stock could re-test its 52-week low of $417.74 and potentially break below it as the growth narrative unravels. Given the current price of $438.10, this implies a realistic immediate downside of approximately -5% to the recent low, with the potential for a -20% to -30% drawdown if sentiment turns decisively negative and multiples contract toward industry averages.
FAQ
The key risks are, in order of severity: 1) Valuation Compression: The high P/E multiples (70x trailing) make the stock vulnerable to derating if growth slows or interest rates rise. 2) Regulatory: The recent FDA flag on a surgical stapler could expand, impacting sales and reputation. 3) Execution: The market expects EPS to jump to $17.08; missing this target would cause a sharp correction. 4) Competitive: While dominant, long-term competition from large medtech firms is a constant threat. The stock's high beta of 1.509 amplifies all these risks.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $480 and $550 as strong fundamentals battle a high valuation. The Bull Case (25% probability) targets a return to $603+ on resolved regulatory issues and earnings beats. The Bear Case (15% probability) sees a drop to the $417-$450 range if risks materialize. The most likely outcome is the Base Case, assuming the company meets its high growth estimates but fails to achieve multiple expansion in the current environment.
ISRG is overvalued relative to the broader market and its medical device peers, but the premium is justified by its superior growth and profitability profile to some degree. Its trailing P/E of 70.78x and forward P/E of 37.16x are significantly above industry averages. The valuation implies the market expects earnings to grow nearly 8x from recent quarterly levels. Therefore, it is fairly valued only if the company hits its aggressive growth targets; it is overvalued if growth decelerates even slightly.
ISRG is a good stock for the right investor at the right price. For long-term investors who believe in the durable growth of robotic surgery, the company's fundamental strengths are undeniable. However, at a forward P/E of 37x, the stock is not a compelling buy today as it prices in near-perfect execution. It would become a more attractive buy if it traded closer to its 52-week low of $417, offering a better margin of safety against its regulatory and valuation risks. The 19% annual decline suggests waiting for stabilization is prudent.
ISRG is primarily suitable for long-term investment (5+ years). Its business model benefits from a long runway of robotic surgery adoption, surgeon training lock-in, and recurring revenue from instruments. The stock's high beta (1.509) and valuation sensitivity make it volatile and risky for short-term trading. The lack of a dividend further emphasizes its role as a pure capital appreciation holding. Investors should be prepared to weather significant volatility, as evidenced by the 29% max drawdown, for the potential of long-term compounding.
